SCHEMBL14699298

SCHEMBL14699298

NC(=O)c1ccc(Cn2c[c]c(C(N)=O)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.40
PLA2G2A P14555 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CYP17A1 P05093 1/20 0.39
PARP10 Q53GL7 1/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 1/20 0.37
HDAC1 Q13547 3/20 0.37
HDAC6 Q9UBN7 3/20 0.37
HSD17B10 Q99714 1/20 0.36
LMNA P02545 1/20 0.36
NAMPT P43490 1/20 0.36
PARP1 P09874 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
KLKB1 P03952 1/20 0.35
CYP2D6 P10635 1/20 0.35
OPRK1 P41145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15520351 0.88 TSHR (0.43) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL15520768 0.87 LMNA (0.40) PARP10ALDH1A1HDAC1HDAC6LMNA
SCHEMBL1718132 0.86 PARP1 (0.48) PLA2G10PLA2G2AKMT2AALDH1A1GAA
SCHEMBL4019841 0.85 CYP17A1 (0.39) KMT2AMEN1CYP17A1KDM4EALDH1A1
SCHEMBL14699416 0.83 HTT (0.43) PLA2G10HDAC1HDAC6KLKB1OPRK1
SCHEMBL15520795 0.83 CYP19A1 (0.43) ALDH1A1HDAC1HSD17B10CYP2C19
SCHEMBL15520091 0.83 CACNA1G (0.43) KMT2AMEN1PARP10ALDH1A1GAA
SCHEMBL15520585 0.80 CACNA1G (0.40) ALDH1A1
SCHEMBL15520762 0.79 CYP11B1 (0.39) HDAC1HDAC6KCNH2
SCHEMBL4024499 0.77 RECQL (0.44) ALDH1A1CYP2C9OPRK1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2742040-B1 INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE HOFFMANN LA ROCHE (CH) 2016-04-06 EP disclosed
US-20140309210-A1 INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2014-10-16 US disclosed
EP-2742040-A1 INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2014-06-18 EP disclosed
WO-2013024011-A1 INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309210-A1 INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF CYP3A43, INSR, CYP2C19 PLA2G10 4541/4885PLA2G2A 4642/4885KMT2A 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.